The association between computed tomography attenuation value of renal angiomyolipoma associated with tuberous sclerosis complex and response to everolimus
Authors:
- 6 January 2024
- journal article
- research article
- Published by Springer Nature in World Journal of Urology
- Vol. 42 (1) , 1-7
Abstract
Background The response to everolimus in patients with renal angiomyolipoma associated with tuberous sclerosis complex (TSC-RAML) varies among individuals. This study aims to identify potential factors associated with the response to everolimus. Method We retrospectively examined data encompassing age, gender, tumor size, computed tomography attenuation value (CT value), CT enhancement, and tumor reduction rate in patients with TSC-RAML undergoing everolimus in two previously registered clinical trials. Result A total of 33 participants (29.33 ± 6.63 years old, 20 females) were included. The correlation analysis conducted separately for tumors located in the left and right kidneys revealed significant negative correlations (P < 0.05) between tumor reduction rate and age, as well as tumor size. While significant positive correlations (P < 0.05) were observed between tumor reduction rate and unenhanced CT value as well as CT enhancement. Nonetheless, based on multiple linear regression analysis, unenhanced CT value emerged as the sole-independent predictor of tumor reduction rate among age, gender, tumor size, unenhanced CT value and CT enhancement for both left (coefficient = 0.00319, P < 0.0001) and right kidneys (coefficient = 0.00315, P = 0.0104). Notable reductions were observed in unenhanced CT value (− 3.81 vs − 24.70HU, P < 0.0001) and CT enhancement (48.16 vs 33.56HU, P < 0.0001) following a 3-month administration of everolimus. The decline in both unenhanced CT value and tumor size predominantly occurred within the initial 3 months, subsequently maintaining a relatively stable level throughout the treatment. Conclusion The unenhanced CT value of TSC-RAML showed an independent correlation with the response to everolimus, suggesting its potential as a predictor of everolimus efficacy in patients with TSC-RAML.Keywords
Funding Information
- National High Level Hospital Clinical Research Funding (2022-PUMCH-B-010)
This publication has 24 references indexed in Scilit:
- Tuberous Sclerosis Complex Surveillance and Management: Recommendations of the 2012 International Tuberous Sclerosis Complex Consensus ConferencePediatric Neurology, 2013
- Tuberous Sclerosis Complex–Associated Angiomyolipomas: Focus on mTOR InhibitionAmerican Journal of Kidney Diseases, 2012
- Burden of disease and unmet needs in tuberous sclerosis complex with neurological manifestations: systematic reviewCurrent Medical Research and Opinion, 2011
- Tuberous Sclerosis Complex: Neurological, Renal and Pulmonary ManifestationsNeuropediatrics, 2010
- Angiomyolipomata: challenges, solutions, and future prospects based on over 100 cases treatedBJU International, 2009
- mTOR Inhibitor RAD001 (Everolimus) Has Antiangiogenic/Vascular Properties Distinct from a VEGFR Tyrosine Kinase InhibitorClinical Cancer Research, 2009
- Changing Trends in Presentation, Diagnosis and Management of Renal Angiomyolipoma: Comparison of Sporadic and Tuberous Sclerosis Complex-associated FormsUrology, 2008
- Role of mTOR in solid tumor systems: a therapeutical target against primary tumor growth, metastases, and angiogenesisCancer and Metastasis Reviews, 2007
- Large renal angiomyolipomas: digital subtraction angiographic grading and presentation with bleedingClinical Radiology, 2006
- Mortality in the Mayo Clinic Tuberous Sclerosis Complex StudyAnnals of the New York Academy of Sciences, 1991